10x Genomics (TXG) reports Q3: everything you need to know ahead of earnings

What happened

10x Genomics is scheduled to report quarterly results this Thursday after the market closes. Last quarter, it reported revenue of $151 million, down 12.6% year over year, while beating analysts’ revenue and earnings-per-share estimates and giving full-year revenue guidance slightly above expectations.

Confirmed

Global impact / market context

The upcoming report will show whether revenue has stabilized: analysts expect it to be flat year over year, an improvement from the 1.7% decline in the same quarter last year. A result below expectations could renew concern about demand and pressure the company’s revenue outlook.

Analyst inference

Analysts generally reaffirmed their estimates in the past 30 days, suggesting limited expectation changes before the report. Peer results offer mixed clues: Illumina and West Pharmaceutical Services both grew revenue and beat estimates, but their performance does not establish how 10x Genomics will fare.

Analyst inference

What to watch

1. Compare reported revenue with the expected flat year-over-year result; growth would indicate improvement, while a decline would show that recent weakness has continued. Confirmed
2. Check whether earnings per share and full-year revenue guidance beat expectations again; stronger results or guidance could support confidence in future sales. Analyst inference
3. Look for management’s explanation of demand and its revenue outlook, since those details may clarify whether flat growth reflects a temporary pause or persistent weakness. Analyst inference

Evidence

• stockstory.org